Scarica l'app Stockscreener
115.09
0.18%
0.21
Pre-mercato:
115.50
0.41
+0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
What to Expect From Incyte's Q2 2026 Earnings Report - Barchart
Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Citizens maintains Incyte stock rating on pipeline progress - Investing.com
INCY Maintains Overweight Rating -- Price Target Raised to $134 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on VWD drug data - Investing.com
H.C. Wainwright reiterates Incyte stock rating on VWD drug data By Investing.com - Investing.com UK
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte (INCY) Reveals Promising Data for New Treatment in Von Wi - GuruFocus
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types - BioBuzz
How Investors May Respond To Incyte (INCY) Latarcibart Data In Von Willebrand Disease Prophylaxis - Yahoo Finance
INCY Maintained by BMO Capital -- Price Target Raised to $112 - GuruFocus
BMO raises Incyte stock price target to $112 on Opzelura strength - Investing.com Australia
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disord - Benzinga
BMO raises Incyte stock price target to $112 on Opzelura strength By Investing.com - Investing.com India
Incyte reports 81% bleeding reduction in VWD study - grafa.com
Incyte reports phase 1/2 trial results for bleeding disorder drug By Investing.com - Investing.com South Africa
Incyte reports phase 1/2 trial results for bleeding disorder drug - Investing.com
Incyte stock holds steady as pipeline progress supports long-term growth outlook - Ad-hoc-news.de
Funds slated to go to Incyte will bankroll corridor improvement program - Delaware Business Now
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Forte, First Tracks soar on CD122 success in vitiligo; celiac next - BioWorld News
Incyte stock steadies on its oncology franchise - ad-hoc-news.de
2 Fast-Growing Pharmaceutical Stocks to Buy Now - Yahoo Finance
Incyte (INCY) Set to Release Q2 2026 Earnings with Positive Mark - GuruFocus
Incyte stock hits 52-week high at 118.77 USD - Investing.com
Incyte stock hits 52-week high at 118.77 USD By Investing.com - Investing.com UK
Incyte to Report Second Quarter 2026 Financial Results - BioSpace
Incyte to Report Second Quarter Financial Results - Business Wire
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists - Investor's Business Daily
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Form 4 Incyte Corporation For: 7 July By Investing.com - Investing.com Canada
INCYTE (INCY) CEO’s RSU tax withholding adjusts reported share holdings - Stock Titan
INCYTE (INCY) CMO has 2,177 shares withheld to cover equity award taxes - Stock Titan
INCY Maintained by RBC Capital -- Price Target Raised to $99.00 - GuruFocus
Incyte Corporation (INCY) Completes Acquisition of Vega Therapeu - GuruFocus
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte (INCY) Completes Acquisition of Vega Therapeutics - GuruFocus
Incyte completes $1.25B acquisition of Vega Therapeutics - grafa.com
Incyte completes $1.25B Vega Therapeutics acquisition By Investing.com - Investing.com South Africa
Incyte completes $1.25B Vega Therapeutics acquisition - Investing.com
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio - Business Wire
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion - Yahoo Finance
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Truist Financial Maintains Incyte(INCY.US) With Hold Rating - Moomoo
INCYTE (INCY) director Paul J. Clancy receives 252-share fully vested stock grant - Stock Titan
Incyte (INCY): Truist Raises the Price Target to $105 as a Government Settlement Adds $246 Million to Net Sales - Insider Monkey
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte Corp gains 16% in a week, boosted by str... - Pluang
Incyte stock: Is INCY outperforming the healthcare sector? - MSN
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura - Yahoo Finance
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
H.C. Wainwright reiterates Incyte stock rating on EU label expansion By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Incyte stock rating on EU label expansion - Investing.com
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
Incyte (INCY) Stock After 66% One-Year Rally Is The Market Too Optimistic Now - Yahoo Finance
Incyte (INCY) Wins EU Backing For Opzelura As Pipeline Data Builds Across Four Drugs - Yahoo Finance
INCY Maintains by UBS -- Price Target Raised to $113 - GuruFocus
UBS raises Incyte stock price target to $113 on biotech recovery By Investing.com - Investing.com Australia
UBS raises Incyte stock price target to $113 on biotech recovery - Investing.com Nigeria
0.27%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):